A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer (Q44487918)

3 December 2017

title

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer (English)

1 reference

3 December 2017

main subject

phase II clinical trial

0 references

author name string

D Scott McMeekin

1

1 reference

3 December 2017

Alan Gordon

2

1 reference

3 December 2017

Jeffrey Fowler

3

1 reference

3 December 2017

Allen Melemed

4

1 reference

3 December 2017

Richard Buller

5

1 reference

3 December 2017

Thomas Burke

6

1 reference

3 December 2017

Jeffery Bloss

7

1 reference

3 December 2017

Paul Sabbatini

8

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

90

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

64-69

1 reference

3 December 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

The epidemiology of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900203-8

7 January 2021

10.1016/S0090-8258(03)00203-8

Identifiers

DOI

1 reference

3 December 2017

1 reference